RVMD
Revolution Medicines
October 20, 2026 · intraday
- Rarity
- 1.34
- Peak move
- +7.47%
- Float cap
- $31.2B
Still running — rarity and peak move can only rise from here.
Revolution Medicines is a late-stage clinical oncology company developing oral targeted therapies for patients with RAS-addicted cancers, including pancreatic and lung tumors. Its pipeline is built on a tri-complex RAS(ON) inhibitor platform, led by daraxonrasib, zoldonrasib, elironrasib and RMC-5127, which are designed to block the active, cancer-driving forms of RAS proteins. Its customers today are clinical trial sites, research collaborators and, prospectively, oncology treatment centers.
Where do you see this going?
no votes yetVote to see the split.
What we found
no events · 0 from SEC or newswire · 0 timed with the moveNothing found.We searched SEC filings, the newswires and the open web across the three days around this move and found no public information that explains it.